ClinicalTrials.gg

Digestive System Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 195 studies for Digestive System Neoplasms across more than 10 countries. 57 are recruiting or about to start. 56 of them are mainly about Digestive System Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 37 narrower conditions too, such as Colorectal Neoplasms: 23,528 studies, 6,459 open.

Status

Completed
76
Recruiting
52
Status unknown
28
Terminated
21
Active, not recruiting
11
Not yet recruiting
5

Phase

Phase 2
63
Phase 1
52
Phase 3
20
Early Phase 1
3
Phase 4
2

Where

China
75
United States
63
France
31
Spain
18
Germany
16
Canada
16

Who develops what

Add Digestive System Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 12 programs from 6 companies, 8 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Sichuan Biokin Pharmaceutical, Pfizer and Sichuan Kelun Pharmaceutical here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
BevacizumabRecent, limited
Evidence
  • NCT07222800 · Pfizer · Phase 3 · live · comparator · “Bevacizumab” · registered Oct 2025
  • NCT04607421 · Pfizer · Phase 3 · live · comparator · “Bevacizumab” · registered Oct 2020
  • NCT02753127 · Sumitomo Pharma Co., Ltd. · Phase 3 · background · “Bevacizumab” · registered Apr 2016
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others11 study
Antineoplastic AgentsRecent, limited
Evidence
  • NCT07222800 · Pfizer · Phase 3 · live · background · “Chemotherapy” · registered Oct 2025
  • NCT02215837 · Shenzhen Hornetcorn Bio-technology Company, LTD · Phase 2 · background · “Chemotherapy” · registered Aug 2014
  • NCT02202928 · Shenzhen Hornetcorn Bio-technology Company, LTD · Phase 2 · background · “Chemotherapy” · registered Jul 2014
—11 study
IrinotecanEarlier only
Evidence
  • NCT02753127 · Sumitomo Pharma Co., Ltd. · Phase 3 · background · “Irinotecan” · registered Apr 2016
  • NCT00838578 · Kyowa Kirin Co., Ltd. · Phase 2 · background · “Irinotecan” · registered Feb 2009
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)00 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 12 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Aug 2027 est.SKB571 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 2 main aimNCT07564466 A Study of SKB571 in Participants With Gastrointestinal Tumors — primary endpoint: Objective response rate (ORR) · 160 enrolled
  • Oct 2027 est.SOS1 Inhibitor MRTX0902 · Kumquat Biosciences Inc. · Phase 2 named, not the main aimNCT07406633 KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) — primary endpoint: Objective response rate (ORR) · 46 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Digestive System Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 4 open · Tyrosine kinase inhibitors (TKIs) 3 open · Angiogenesis inhibitors 1 open · Antimetabolites 7 · Antimitotic agents 7

Coming up

25studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 52 Digestive System Neoplasms studies recruiting now, 27 (52%) set no upper age limit and 17 (33%) stop at 75 or younger. 2 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (2%) take healthy volunteers.

Recruiting studies that take each age, of 52
AgeWomenMen
101 (2%)1 (2%)
1849 (94%)49 (94%)
3050 (96%)50 (96%)
4051 (98%)51 (98%)
5052 (100%)52 (100%)
6552 (100%)52 (100%)
7549 (94%)49 (94%)
8531 (60%)31 (60%)

Across all 195 studies, recruiting or not: 20% stop at 75 or younger and 2% at 65; 3% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Digestive System Neoplasms studies take

Of 29 phase 2 interventional studies under Digestive System Neoplasms, half reached primary completion within 44 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 244 mo33–61 · 29 studies——
Interventional, no phase20 mo15–… · 24 studies——
Observational36 mo14–102 · 24 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 195. Browse all 195 → or search them.